FARE - Food Allergy Research & Education Logo

Boiled Peanut Immunotherapy for the Treatment of Peanut Allergy

Study Purpose

Peanut allergy is the most common cause of severe allergic reactions to food. Onset is common in childhood, but in contrast to other food allergies such as cow's milk and egg, peanut allergy tends to persist into adulthood. It is associated with a significant impact on quality of life, both for the affected individual and their family. There is no current cure for peanut allergy. Oral peanut immunotherapy (OIT) using defatted, roasted peanut flour has been demonstrated to offer potential in this regard, but is associated with significant and frequent reactions and can cause life-threatening allergic symptoms. The investigators have previously demonstrated that the processing of peanuts through boiling results in a relatively hypoallergenic product due to the loss of key allergenic components from peanut into the water. This has been tested in a recently-completed Phase 2b/3 trial (The BOPI Study, Clinicaltrials.gov NCT02149719; HRA reference 15/LO/0287): 47 children/ young people with peanut allergy confirmed at double-blind, placebo-controlled food challenge (DBPCFC) were randomised (2:1) to receive either oral immunotherapy (updosing using boiled peanut for ~6 months, followed by maintenance with roasted peanut) or standard treatment (allergen avoidance). Participants underwent repeat DBPCFC at 12 months to assess response, following which peanut OIT was stopped and sustained unresponsiveness assessed after 4 weeks (4SU). 24/32 participants (100% per protocol) achieved the primary outcome of desensitisation to >1.44g peanut protein (approximately 6-8 peanuts, p<0.0001); of those 14 tolerated >4.4g peanut protein. 13/24 participants achieved 4SU. There was no significant change in threshold in the control group (p>0.05). Boiled peanut OIT had a favourable safety profile, with under 2% of doses associated with gastrointestinal symptoms. The BOPI-2 study is a non-inferiority study to demonstrate that boiled peanut is at least as effective as peanut flour in treating children with peanut allergy. The study will compare the rate of adverse events and other safety outcomes between these two interventions, and assess the immunological mechanisms involved, a secondary aim being to develop clinically-useful predictors for identifying individuals likely to undergo successful desensitisation.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 7 Years - 18 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Age 7-18 years (enrolment up to a participant's 19th birthday).
  • - Past history consistent with IgE-mediated peanut allergy - Allergic to ≤1.44 g peanut protein (approx.
6 peanuts) at baseline double-blind placebo-controlled food challenge, prior to treatment allocation
  • - Tolerates at least 1/8 boiled peanut (boiled for 4 hours) at open food challenge at screening.
  • - Written informed consent of parent/legal guardian and patient assent.

Exclusion Criteria:

  • - Required previous admission to an intensive care unit for management of an allergic reaction to peanut.
  • - Clinically significant chronic illness (other than asthma, rhinitis or eczema).
  • - Undergoing subcutaneous or sublingual immunotherapy to respiratory allergens, and not yet established on maintenance dosing for at least 3 months.
  • - Undergoing oral immunotherapy for food allergy and within the first year of treatment.
  • - Subjects receiving anti-IgE therapy, oral immunosuppressants, beta-blocker or ACE inhibitor.
  • - Tolerance to ≥1.44 g peanut protein (approx.
6 peanuts) at initial DBPCFC during screening.
  • - Dose-limiting symptoms to 1/8 boiled peanut (boiled for 4 hours) at screening.
  • - Poorly controlled asthma within the previous 3 months (as defined by clinician judgement with reference to the ICON consensus ), or asthma requiring treatment with >5 days oral corticosteroids within the previous 3 months.
- Pregnancy - Unwilling or unable to fulfil study requirements

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT03937726
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

N/A
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Imperial College London
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Paul J Turner, FRACP PhD
Principal Investigator Affiliation Imperial College London
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

OtherOther
Overall Status Recruiting
Countries United Kingdom
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

IgE Mediated Peanut Allergy, Peanut Hypersensitivity
Study Website: View Trial Website
Arms & Interventions

Arms

Experimental: Boiled peanut Oral Immunotherapy

Desensitisation using boiled peanut

Active Comparator: Conventional Oral immunotherapy

Desensitisation using defatted peanut flour

Interventions

Other: - Boiled peanut

Desensitisation using boiled peanut for induction and initial updosing

Other: - Defatted roasted peanut flour

Desensitisation using defatted peanut flour for induction and initial updosing

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

London, United Kingdom

Status

Recruiting

Address

Imperial College Healthcare NHS Trust (St. Mary's Hospital)

London, ,

Site Contact

Paul J Turner

p.turner@imperial.ac.uk

+44 20 3312 7754

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.